Mayara Martina Abatti Chiamulera1,2,3, Caroline Biazzolo Zancan1,2, Aline Pertile Remor1,2, Marcos Freitas Cordeiro1,2, Frederico Omar Gleber-Netto4, Antuani Rafael Baptistella5,6,7. 1. Universidade do Oeste de Santa Catarina (UNOESC), Joacaba, SC, Brazil. 2. Programa de Pos-Graduacao em Biociencias e Saude/Universidade do Oeste de Santa Catarina, Joacaba, SC, Brazil. 3. Hospital Universitario Santa Terezinha, Joacaba, SC, Brazil. 4. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Universidade do Oeste de Santa Catarina (UNOESC), Joacaba, SC, Brazil. antuani.baptistella@unosec.edu.br. 6. Programa de Pos-Graduacao em Biociencias e Saude/Universidade do Oeste de Santa Catarina, Joacaba, SC, Brazil. antuani.baptistella@unosec.edu.br. 7. Hospital Universitario Santa Terezinha, Joacaba, SC, Brazil. antuani.baptistella@unosec.edu.br.
Abstract
BACKGROUND: Oral cancer (OC) is usually diagnosed at advanced clinical stages due to its asymptomatic nature and absence of pathognomonic signs in its early development phase. Delayed diagnosis is one of the major causes of OC treatment failure and poor prognosis. Development of alternative diagnostic approaches are imperative for improving early detection and therapeutic success rates. Salivary cytokines (SC) have been studied as potential diagnostic biomarkers for OC and may represent a potential tool for improvement of its early detection. METHODS: In this systematic review and meta-analysis we identified SC studied as OC biomarkers by systematically reviewing the PubMed and Cochrane Library databases using the terms: "oral cancer", "cytokine", and "saliva", and also combined with "interleukin" or "interferon". Only case-control studies that measured SC by ELISA from treatment naïve patients were included in the qualitative review. For the meta-analysis were included all comparable studies that provided enough data (sample size, mean and standard deviation or standard error of the mean) for SC levels in OC patients, non-cancer controls and patients with oral potentially malignant disorders (OPMD), including leukoplakia. Comparisons with patients with oral lichen planus (OLP) and gingivitis were included in the qualitative analysis. RESULTS: A total of 28 articles (from 2004 to 2018) were included in the systematic review, describing 10 different SC, being IL-8 and IL-6 the most studied ones. SC levels were consistently higher among OC patients when compared to healthy controls and to patients with OPMD, OLP and gingivitis. Meta-analysis including 23 eligible studies showed that IL-8, IL-6, TNF-α, IL-1β and IL-10 salivary levels were significantly higher in OC patients compared to controls; and that IL-8, IL-6, TNF-α and IL-1β salivary levels were also higher in OC patients compared to individuals with OPMD. When compared to healthy controls, OPMD patients showed significantly higher IL-6 and TNF-α salivary levels. CONCLUSIONS: Our analyses showed that the salivary levels of some cytokines are consistently different among OC, OPMD and healthy patients, indicating that these SC may represent potential diagnostic biomarkers for OC and OPMD. Despite of that, SC levels were highly variable among studies, suggesting that further technical improvement and standardization for SC measurement by ELISA is needed in order to successfully translate these biomarkers to the clinical practice.
BACKGROUND:Oral cancer (OC) is usually diagnosed at advanced clinical stages due to its asymptomatic nature and absence of pathognomonic signs in its early development phase. Delayed diagnosis is one of the major causes of OC treatment failure and poor prognosis. Development of alternative diagnostic approaches are imperative for improving early detection and therapeutic success rates. Salivary cytokines (SC) have been studied as potential diagnostic biomarkers for OC and may represent a potential tool for improvement of its early detection. METHODS: In this systematic review and meta-analysis we identified SC studied as OC biomarkers by systematically reviewing the PubMed and Cochrane Library databases using the terms: "oral cancer", "cytokine", and "saliva", and also combined with "interleukin" or "interferon". Only case-control studies that measured SC by ELISA from treatment naïve patients were included in the qualitative review. For the meta-analysis were included all comparable studies that provided enough data (sample size, mean and standard deviation or standard error of the mean) for SC levels in OCpatients, non-cancer controls and patients with oral potentially malignant disorders (OPMD), including leukoplakia. Comparisons with patients with oral lichen planus (OLP) and gingivitis were included in the qualitative analysis. RESULTS: A total of 28 articles (from 2004 to 2018) were included in the systematic review, describing 10 different SC, being IL-8 and IL-6 the most studied ones. SC levels were consistently higher among OCpatients when compared to healthy controls and to patients with OPMD, OLP and gingivitis. Meta-analysis including 23 eligible studies showed that IL-8, IL-6, TNF-α, IL-1β and IL-10 salivary levels were significantly higher in OCpatients compared to controls; and that IL-8, IL-6, TNF-α and IL-1β salivary levels were also higher in OCpatients compared to individuals with OPMD. When compared to healthy controls, OPMD patients showed significantly higher IL-6 and TNF-α salivary levels. CONCLUSIONS: Our analyses showed that the salivary levels of some cytokines are consistently different among OC, OPMD and healthy patients, indicating that these SC may represent potential diagnostic biomarkers for OC and OPMD. Despite of that, SC levels were highly variable among studies, suggesting that further technical improvement and standardization for SC measurement by ELISA is needed in order to successfully translate these biomarkers to the clinical practice.
Entities:
Keywords:
Biomarkers; Cytokines; Head and neck cancer; Oral cancer; Saliva
Authors: Maie A R St John; Yang Li; Xiaofeng Zhou; Paul Denny; Chih-Ming Ho; Carlo Montemagno; Wenyuan Shi; Fengxia Qi; Benjamin Wu; Uttam Sinha; Richard Jordan; Lawrence Wolinsky; No-Hee Park; Honghu Liu; Elliot Abemayor; David T W Wong Journal: Arch Otolaryngol Head Neck Surg Date: 2004-08
Authors: Miguel Ángel González-Moles; Saman Warnakulasuriya; María López-Ansio; Pablo Ramos-García Journal: Cancers (Basel) Date: 2022-08-08 Impact factor: 6.575
Authors: Jebrane Bouaoud; Paolo Bossi; Moshe Elkabets; Sandra Schmitz; Léon C van Kempen; Pierre Martinez; Sankar Jagadeeshan; Ingrid Breuskin; Gerwin J Puppels; Caroline Hoffmann; Keith D Hunter; Christian Simon; Jean-Pascal Machiels; Vincent Grégoire; Chloé Bertolus; Ruud H Brakenhoff; Senada Koljenović; Pierre Saintigny Journal: Cancers (Basel) Date: 2022-04-02 Impact factor: 6.639
Authors: Elena Ferrari; Margherita E Pezzi; Diana Cassi; Thelma A Pertinhez; Alberto Spisni; Marco Meleti Journal: Int J Mol Sci Date: 2021-06-24 Impact factor: 5.923
Authors: Catherine Laliberté; Nicole Ng; Denise Eymael; Kevin Higgins; Aiman Ali; Alex Kiss; Grace Bradley; Marco A O Magalhaes Journal: Front Oral Health Date: 2021-09-21